Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

Blood Cancer J. 2015 Dec 11;5(12):e375. doi: 10.1038/bcj.2015.103.

¹ Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Service des Maladies du Sang, Centre François Magendie, Hôpital du Haut-Lévèque, Pessac, France.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Department of Adult Hematology, Hôpital Saint Louis, Paris, France.
⁵ Department of Hematology, Hôpital Hotel Dieu, Nantes, France.
⁶ Department of Hematology, Hôpital Edouard Herriot, Lyon, France.
⁷ Clinical Biomarkers, Merck KGaA, Darmstadt, Germany.
⁸ Clinical Oncology, Early Development, EMD Serono, Billerica, MA, USA.
⁹ Global Biostatistics, Hematologic Cancer and BMT, Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, MD, USA.

No abstract available

Publication types